Hepatology

Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction

A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.

Alcohol and Sugar: A Dual Metabolic Challenge for Patients

Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.

EASL Congress 2026: Key Trials to Watch in Liver Disease Management

EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.

Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies

EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.

EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment

EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.

EASL 2026 Forum: Enhancing Patient-Clinician Communication

The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.

EASL 2026: Alcohol Policy Action Needed for Liver Disease

The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.

A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis

New A-TANGO organ failure score refines acute-on-chronic liver failure (ACLF) diagnosis and prognostication in hospitalised cirrhosis patients.

MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines

Despite 2024 EASL guidelines for MASLD, physicians encounter significant barriers in screening and diagnosis, particularly in SEEMEA.

EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging

EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.